BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 18638092)

  • 1. Tissue plasminogen activator as a hemodialysis catheter locking solution.
    McGill RL; Spero JA; Sysak JC; Sandroni SE; Marcus RJ
    Hemodial Int; 2008 Jul; 12(3):348-51. PubMed ID: 18638092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue plasminogen activator (t-PA) efficacy in the restoration of hemodialysis catheter function.
    Meers C; Toffelmire EB
    CANNT J; 1999; 9(4):25-8. PubMed ID: 15714785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of catheter-restricted filling with cefotaxime and heparin on the lifespan of temporary hemodialysis catheters: a case controlled study.
    Saxena AK; Panhotra BR
    J Nephrol; 2005; 18(6):755-63. PubMed ID: 16358235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Tissue plasminogen activator antigen (t-PA Ag) and tissue plasminogen activator inhibitor (PAI-1) in the course of hemodialysis in patients with chronic renal failure].
    Piatkowska M; Kotschy M; Nartowicz E; Rajewski W
    Pol Merkur Lekarski; 1997 Jan; 2(9):205-7. PubMed ID: 10907030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical consequences of heparin-free hemodialysis.
    McGill RL; Blas A; Bialkin S; Sandroni SE; Marcus RJ
    Hemodial Int; 2005 Oct; 9(4):393-8. PubMed ID: 16219060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of tissue plasminogen activator for thrombolysis in occluded peritoneal dialysis catheters in children.
    Shea M; Hmiel SP; Beck AM
    Adv Perit Dial; 2001; 17():249-52. PubMed ID: 11510286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concentration of heparin-locking solution and risk of central venous hemodialysis catheter malfunction.
    Thomas CM; Zhang J; Lim TH; Scott-Douglas N; Hons RB; Hemmelgarn BR;
    ASAIO J; 2007; 53(4):485-8. PubMed ID: 17667236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant tissue plasminogen activator is a useful alternative to heparin in priming quinton permcath.
    Schenk P; Rosenkranz AR; Wölfl G; Hörl WH; Traindl O
    Am J Kidney Dis; 2000 Jan; 35(1):130-6. PubMed ID: 10620554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Restoration of patency in failing tunneled hemodialysis catheters: a comparison of catheter exchange, exchange and balloon disruption of the fibrin sheath, and femoral stripping.
    Janne d'Othée B; Tham JC; Sheiman RG
    J Vasc Interv Radiol; 2006 Jun; 17(6):1011-5. PubMed ID: 16778235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic and acute consequences of a post-dialysis urokinase lock on permanent hemodialysis catheter function.
    Gabutti L; Mosconi E; Pellegrini L; Duchini F; Marone C
    J Nephrol; 2006; 19(2):183-8. PubMed ID: 16736417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reteplase for dysfunctional hemodialysis catheter clearance.
    Hilleman DE; Dunlay RW; Packard KA
    Pharmacotherapy; 2003 Feb; 23(2):137-41. PubMed ID: 12587800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of tissue plasminogen activator infusion to re-establish function of tunneled hemodialysis catheters.
    Dowling K; Sansivero G; Stainken B; Siskin G; Dolen E; Ahn J; Mitchell N
    Nephrol Nurs J; 2004; 31(2):199-200. PubMed ID: 15114800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Tesio twin catheter system for hemodialysis tunnelized using an echo-guided technique. Retrospective analysis of 210 catheters].
    Ibrik O; Samon R; Roca R; Viladoms J; Mora J
    Nefrologia; 2006; 26(6):719-25. PubMed ID: 17227250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator.
    Hemmelgarn BR; Moist LM; Lok CE; Tonelli M; Manns BJ; Holden RM; LeBlanc M; Faris P; Barre P; Zhang J; Scott-Douglas N;
    N Engl J Med; 2011 Jan; 364(4):303-12. PubMed ID: 21268722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A longitudinal study of the repeated use of alteplase as therapy for tunneled hemodialysis catheter dysfunction.
    Little MA; Walshe JJ
    Am J Kidney Dis; 2002 Jan; 39(1):86-91. PubMed ID: 11774106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombosis of tunneled-cuffed hemodialysis catheters: treatment with high-dose urokinase lock therapy.
    Donati G; Colì L; Cianciolo G; La Manna G; Cuna V; Montanari M; Gozzetti F; Stefoni S
    Artif Organs; 2012 Jan; 36(1):21-8. PubMed ID: 21848863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Occluded Tunneled Venous Catheter in Hemodialysis Patients: Risk Factors and Efficacy of Alteplase.
    Ponce D; Mendes M; Silva T; Oliveira R
    Artif Organs; 2015 Sep; 39(9):741-7. PubMed ID: 25894244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short and long alteplase dwells in dysfunctional hemodialysis catheters.
    Macrae JM; Loh G; Djurdjev O; Shalansky S; Werb R; Levin A; Kiaii M
    Hemodial Int; 2005 Apr; 9(2):189-95. PubMed ID: 16191068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Restoration of flow following haemodialysis catheter thrombus. Analysis of rt-PA infusion in tunnelled dialysis catheters.
    Davies J; Casey J; Li C; Crowe AV; McClelland P
    J Clin Pharm Ther; 2004 Dec; 29(6):517-20. PubMed ID: 15584939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Locking solutions for hemodialysis catheters; heparin and citrate--a position paper by ASDIN.
    Moran JE; Ash SR;
    Semin Dial; 2008; 21(5):490-2. PubMed ID: 18764795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.